Hopefully Peregrine monitoring the landscape for those stepping into IP Targeting without possibly knowing or maybe a license is already in the works for many others like the one below ...
"Our NOxBR application is based on proprietary technology that utilizes inhalations of nitric oxide for several consecutive days until elimination of the disease. NOxBR was successful in a Phase II clinical study. We are currently in preparation for phase IIIa clinical trials for NOxBR." http://www.ait-pharm.com/products/noxbr/
Market Data 
Markets 
AI
